ANDOVER, Mass., June 2, 2014 /PRNewswire/ -- According to a new study released today at SLEEP 2014 by Philips Respironics, a division of Royal Philips (NYSE: PHG, AEX: PHI), patients using the SleepMapper mobile app and web-based solution achieved a 22 percent higher positive airway pressure (PAP) therapy adherence rate than non-users. The results of the study further the evidence that patient engagement in care can lead to behavioral change and ultimately, better results and healthier populations.
Obstructive sleep apnea (OSA) is a serious medical condition that can lead to significant personal health consequences and increased overall healthcare costs. Treatment with PAP therapy is considered the gold standard for addressing OSA, but therapy is only effective if patients use their device as prescribed. Patients new to PAP therapy often struggle adapting to the equipment and lack of proper use puts patients' health at risk and may also prompt insurers to refuse to pay for further therapy.
"Healthcare is changing and if you're in the business of making people healthier, you're in the business of behavior change," said Dr. Mark Aloia, Senior Director of Global Clinical Research for Philips Healthcare. "Study results of SleepMapper demonstrate that technology can shape how patients respond to PAP therapy by improving engagement and motivation and ultimately leading them to a better course of treatment for their chronic condition."
To test the effectiveness of SleepMapper, researchers randomly analyzed over 15,000 patients from the Philips Respironics EncoreAnywhere database and compared adherence and usage rates between those who were provided with SleepMapper upon initial PAP setup and those who were not. Patients who were provided with SleepMapper achieved a 78 percent adherence rate based upon the Centers for Medicare and Medicaid (CMS) guidelines, compared to the average 56 percent compliance rate among patients who were not provided with SleepMapper.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts